期刊文献+

常见革兰阴性杆菌对头孢他啶的耐药调查 被引量:3

Drug Resistance to Ceftazidime in Common Gram-negative Bacilli: A Survey
暂未订购
导出
摘要 目的探讨我院常见革兰阴性杆菌对头孢他啶(ceftazidime , CAZ)的耐药现状,为临床遏制细菌对头孢他啶耐药性提供帮助. 方法分析我院2001年1月~2004年6月住院患者标本中,分离出的2 779株病原菌对CAZ的药敏试验结果. 结果铜绿假单胞菌、假单胞菌属、大肠埃希菌、肺炎克雷伯菌、阴沟肠杆菌和不动杆菌属主要革兰阴性杆菌,对CAZ的耐药率分别由2001年的3%、13%、14%、14%、28%、11%上升到2004年的13%、36%、16%、22%、53%、57%. 结论常见革兰阴性杆菌对CAZ的耐药率有逐渐上升的趋势,要严格限制该药的不合理应用. OBJECTIVE To survey drug resistance to ceftazidime(CAZ) in common Gram-negative bacilli in our hospital and thereby to bring the situation under control. METHODS A total of 2 779 strains of pathogenic bacteria were isolated from patients from Jan 2001 to Jun 2004, and drug resistance of these strains to CAZ was examined. RESULTS Resistance of Pseudornonas aeruginosa, Pseudornonas spp, Escherichia coli, Klebsiella pneurnoniae, Enterobacter cloacae and Acinetobacter spp to CAZ was found to be tend increasing from 3%, 13%, 14%, 14%, 28% and 11% in 2001 to 13%, 36%, 16%, 22%, 53% and 57% in 2004, respectively. CONCLUSIONS Resistance ratio of common Gram-negative bacilli to CAZ is high and tend to increase further. CAZ abuse needs to be given appropriate attention.
机构地区 武汉市第三医院
出处 《中华医院感染学杂志》 CAS CSCD 北大核心 2005年第9期1047-1048,共2页 Chinese Journal of Nosocomiology
关键词 革兰阴性杆菌 抗生素耐药 头孢他啶 Gram-negative bacilli Antibiotic resistance Ceftazidime
  • 相关文献

参考文献12

二级参考文献52

  • 1金少鸿.抗生素在食用动物中的应用以及食源性疾病对人类健康的影响[J].中华微生物学和免疫学杂志,2001,21(S1):25-25. 被引量:8
  • 2李立津,官兰.氟喹诺酮等抗菌药物体外抗菌活性及其临床意义[J].中华内科杂志,1993,32(3):148-151. 被引量:1
  • 3郭文学,官兰,吴瑾,刘德孟,宋诗铎,胡文芝.五种氟喹诺酮类药物对临床分离致病菌的体外抗菌活性[J].天津医药,1996,24(10):611-613. 被引量:1
  • 4[1]Jacoby GA,Mederiros AA. More extended-spectrum β-lactamases[J]. Antimicrob Agents Chemother,1991, 35(9):1697-1704.
  • 5[4]Sanders CC,Barry AL, Washington JA, et al. Detection of extended-spectrum β-lactamases-producing members of the family Enterobacteriaceae with the VITEK ESBLs test [J]. J Clin Microbiol, 1996,34(12): 2997-3001.
  • 6[5]Livermore DM. β-Lactamases in laboratory and clinical resistance [J]. J Clin Microbiol Rev, 1995, 8(3): 557-584.
  • 7[6]National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. Ninth informational supplement [S]. NCCLS, 1999.19: 36-75.
  • 8[9]Rasmussen BA, Bush K. Carbapenem-hydrolyzing β-lactamases [J]. Antimicrob Agents Chemother, 1997, 41(2): 223-232.
  • 9[10]Coudron PE, Molaand ES, Thomoson KS. Occurrence and detection of AmpC β-lactamases among Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates at a veterans medical center[J]. J Clin Microbiol, 2000, 38(5):1791-1796.
  • 10[11]Jacoby GA, Han P. Detection of extended-spectrum β-lactamases in clinical isolates of Klebsiella pneumoniae and Escherichia coli [J]. J Clin Microbiol, 1996, 34(4): 908-911.

共引文献351

同被引文献23

引证文献3

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部